Sangamo Therapeutics Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to Sangamo Therapeutics Reports First Quarter 2017 Financial Results
May 10, 2017 4:03 PM EDT
Sangamo Biosciences (NASDAQ: SGMO) reported Q1 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $3.43 million versus the consensus estimate of $4.25 million.
For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.
...
More
May 10, 2017 4:03 PM EDT
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) today announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo's four lead product candidates, which Sangamo expects will enter the clinic this quarter.
"Sangamo brings deep scientific and technical expertise across multiple genomic platforms, and we look forward to working together to advance this potentially transformative treatment for patients living with Hemophilia A," said Mikael Dolsten, MD, PhD, President of Worldwide... More
